Efficacy of ChemoID® guided drug selection for palliative chemotherapy in advanced recurrent high-grade ovarian adenocarcinoma: Case study
Submitted: 9 March 2017
Accepted: 21 March 2017
Published: 13 October 2017
Accepted: 21 March 2017
Abstract Views: 1361
PDF: 487
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Similar Articles
- Candace M. Howard, Jagan Valluri, Pier Paolo Claudio, Functional drug response assay for cancer stem cells in the era of precision medicine , Translational Medicine Reports: Vol. 1 No. 1 (2017)
You may also start an advanced similarity search for this article.